The Effect of Everolimus on the Pharmacokinetics of Tacrolimus in Renal Transplant Patients, and the Effect of ABCB1CYP3A4CYP3A5PORGenetic Polymorphism on the Two Drugs

Trial Profile

The Effect of Everolimus on the Pharmacokinetics of Tacrolimus in Renal Transplant Patients, and the Effect of ABCB1CYP3A4CYP3A5PORGenetic Polymorphism on the Two Drugs

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 01 Feb 2017

At a glance

  • Drugs Everolimus (Primary) ; Mycophenolate mofetil; Tacrolimus
  • Indications Renal transplant rejection
  • Focus Pharmacokinetics
  • Most Recent Events

    • 20 Jan 2017 Planned End Date changed from 1 Dec 2016 to 1 Jan 2018.
    • 20 Jan 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Jan 2018.
    • 06 Jul 2015 Planned End Date changed from 1 Dec 2014 to 1 Dec 2016, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top